VF in the News

ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis

October 8. 2021 ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis ChemoCentryx announced today that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan) as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and specifically for granulomatosis with polyangiitis…...

Read more

New Handout Provides Family Planning and Birth Control Information

We are excited to introduce the release of our new handout designed for our patients who have questions about family planning and birth control. The two-page handout is intended to offer a reference for patients to use when talking with their health care providers about these important issues. The handout…...

Read more

Polymyalgia Rheumatica Research Study

Help Advance Polymyalgia Rheumatica (PMR) Research from Home and Earn $100 The Vasculitis Foundation is reaching out to the Polymyalgia Rheumatica (PMR) patient community to raise awareness about an opportunity for patients to help advance research from home. You need to be 18 years of age or older with PMR…...

Read more

Chronic Illness: Wegener’s Vasculitis Series with Art Diaz

Formerly called Wegener’s granulomatosis, granulomatosis with polyangiitis (GPA) is a form of vasculitis—a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. It is a rare disease that, like so many others, effects each person differently. In…...

Read more